Fruquintinib in mCRC: Key Insights From FRESCO-2

EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC

Now Viewing

EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2

EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions

EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care

EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Video content above is prompted by the following:

1. New to our arsenal of drugs is fruquintinib, an additional option for previously treated metastatic colorectal cancer based on the FRESCO-2 data. What are some highlights of this data in terms of the study population, efficacy, and safety?
2. Include in this discussion that all patients previously received regorafenib or FTD/TPI.
3. What has been your experience using fruquintinib in practice, and how do patient outcomes compare with what was seen in FRESCO-2?